Abstract
Background: The objective of this study was to evaluate the effectiveness of early use of helmet continuous positive airway pressure (CPAP) in reducing mortality in patients with COVID-19 related ARDS
Methods: Demographic and clinical hospital records from patients with a confirmed COVID-19 diagnosis, between the 1st and 30th of March 2020, were analyzed.
Results: 185 patients, 68% male (mean age 72yrs) were included in the analysis. Of the 185 patients, 107 (58%) used only oxygen; 78 underwent CPAP treatment, 32 (41%) were not compliant to CPAP and refuse it (non-compliant group). A total of 46 (25%) patients died overall. Among patients underwent CPAP, a lower mortality was in the CPAP-compliant group (7%) as compared to the non-compliant CPAP group (81%).
To evaluate the effectiveness of early use of CPAP, mortality data has been analyzed between 2 subgroups patients who underwent CPAP <3rd day and ≥3rd day of hospitalization. Twenty-seven patients received CPAP within 2 days from hospitalization, and nineteen from the 3rd day.
No deaths have been observed in the subgroup of patient underwent early CPAP intervention, while the mortality rate was 16% in those underwent CPAC >3 days from the hospitalization.
Conclusion: This retrospective study indicated that in hospitalized patients with ARDS secondary to COVID-19, an early use of CPAP reduces mortality.
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA1769.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021
